v3.26.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Apr. 30, 2026
Apr. 30, 2025
Cash flows from operating activities    
Net loss $ (131,612) $ (113,814)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 8,709 7,968
Loss on disposal of property and equipment 1,161 1,340
Reserve for equipment and supplies 2,435 754
Provision for uncollectible accounts receivable 2,596 2,694
Amortization (accretion) of premiums (discounts) on securities, net (106)  
Interest paid-in-kind   855
Amortization of debt discounts and issuance costs 1,874 1,400
Share-based compensation expense 33,644 24,270
Non-cash lease expense 326 416
Deferred income tax expense 166 64
Change in fair value of warrant liabilities (2,673) 2,648
Changes in operating assets and liabilities:    
Disposable medical equipment supplies (458) (3,443)
Prepaid expenses and other current assets (563) (1,852)
Accounts receivable (9,056) (8,777)
Accounts payable 4,302 2,842
Accrued liabilities 8,197 4,617
Operating lease liabilities (685) 370
Other long-term assets 40 40
Net cash used in operating activities (81,703) (77,608)
Cash flows from investing activities    
Purchases of property and equipment (34,892) (22,936)
Deposits for medical rental equipment (528) (655)
Refund of deposits for medical rental equipment 184 283
Investment in equity security (5,000)  
Purchase of marketable securities (163,041)  
Net cash used in investing activities (203,277) (23,308)
Cash flows from financing activities    
Proceeds from issuance of redeemable preferred stock   103,400
Proceeds from issuance of common stock 149,291 215,789
Proceeds from issuance of stock to non-controlling interest   17,100
Proceeds from capital contributions   2,374
Payments of IPO offering costs   (3,523)
Payment of equity issuance costs (2,466) (3,224)
Deemed dividend for payments to third party on behalf of shareholder (323) (1,654)
Proceeds from stock option exercises 593  
Net cash provided by financing activities 147,095 330,262
Net increase (decrease) in cash, cash equivalents and restricted cash (137,885) 229,346
Cash, cash equivalents and restricted cash    
Beginning of period 237,929 8,583
End of period 100,044 237,929
Reconciliation of cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheets    
Cash and cash equivalents 99,710 237,595
Restricted cash 334 334
Cash, cash equivalents and restricted cash 100,044 237,929
Non-cash investing and financing activities:    
Purchases of property and equipment in accrued liabilities and accounts payable 8,314 7,029
Exercise of liability classified warrant 4,055  
Remeasurement of lease liability 1,614  
Equity offering costs incurred but not yet paid 415 1,875
Deemed dividend for payments to third party on behalf of shareholder included in accrued liabilities and accounts payable 172  
Issuance of warrants related to long term debt   5,449
Conversion of redeemable preferred stock into Common Shares on completion of IPO   280,510
Supplemental disclosure of cash flow information    
Income taxes paid 13 83
Interest paid $ 5,645 $ 4,851